News

Video: Have the tables turned? Rethinking big pharma and biotech’s approach to niche markets

January 4th, 2012 - Tags: , ,

There is a rising interest in assets in some of the most sought-after therapeutic areas: those where access is all but assured, patients are more easily identified, and the commercial call-point is narrow. Ben Bonifant, Practice Area Leader at Campbell Alliance, moderates as the panel takes a look at trends revealed through Campbell Alliance’s Dealmakers’ Intentions Survey and examines the implications for the year ahead.

© 2012 EBD Group AG


Share:
  • email
  • LinkedIn
  • Twitter
  • Facebook
  • Google Bookmarks
  • Yahoo! Bookmarks
  • RSS

Related Posts

  1. Competition forces creativity in niche markets
  2. Video: A look at recently renegotiated deals
  3. Video: Non-traditional partnerships in the new healthcare ecosystem

Latest Posts

  1. Epizyme: Intensive dealmaking in pursuit of personalized therapeutics
  2. Forma Therapeutics: Structured acquisitions to fix broken biotech model
  3. Foundation Medicine: Molecular information disrupting the oncology universe

Newsletter

Subscribe to partneringNEWS
An online journal for executives in the life sciences, partneringNEWS™ is focused on the people behind the deals. Putting a human face to a collaboration agreement gives business development professionals the ability to get behind the headlines.

Sign up today to the free newsletter and never miss any new content.